CLPT · NASDAQ
ClearPoint Neuro, Inc.
$9.04 -0.10 (-1.09%)
Company overview
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct and intra-procedural magnetic resonance imaging (MRI) guidance. It offers the ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and the ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc., Koninklijke Philips N.V., Blackrock Neurotech, and University of California, San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NASDAQ
- Market cap
- $276M
- Employees
- 115
- Headquarters
- Solana Beach, CA
- Website
- clearpointneuro.com
- CEO
- Joseph Michael Burnett
- Listed
- May 22, 2012
- P/E
- -8.95
- Dividend yield
- 0.00%
Company financials
- Revenue
- $40.6M
- Gross profit
- $25.1M
- Operating income
- -$26.5M
- EBITDA
- -$23.9M
- Net income
- -$29.1M
- EPS
- -$1.01
- Total assets
- $93.4M
- Total debt
- $63.6M
- Gross margin
- 61.82%
- Net margin
- -71.57%
- Earnings yield
- -11.17%
No geographic segmentation.
Showing FY 2025
CLPT
1D
NASDAQ
O9.19H9.22L8.95C9.14-0.11 (-1.19%)Vol355.47K